Literature DB >> 8362968

A putative marker for human melanoma. A monoclonal antibody derived from the melanoma gene in the Xiphophorus melanoma model.

J R Vielkind1, V A Tron, B M Schmidt, G J Dougherty, V C Ho, B W Woolcock, B Sadaghiani, C J Smith.   

Abstract

A MoAb was raised against a peptide corresponding to an exposed domain of the putative tyrosine kinase receptor protein encoded by Xmrk, a gene involved in melanoma formation and/or progression in the Xiphophorus fish melanoma model. The antibody reacts specifically with cells from human melanocytic lesions, ie, common acquired nevi, primary and metastatic melanoma biopsies. No reactivity with other cells, including normal melanocytes, was observed in the biopsies or with cells in biopsies from normal tissue (skin, liver, lung, spleen) and from other malignancies including those of neuroectodermal origin. The reactivity was very weak and variable in metastatic melanomas but very strong and characteristic of a receptor-type antigen in primary melanomas, a stage in melanoma progression in which cells have acquired metastasizing potential. It is suggested that the antigen recognized may be involved in growth promotion and represents the human equivalent of the fish melanoma gene product.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8362968      PMCID: PMC1887202     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

Review 1.  Cutaneous melanoma.

Authors:  H K Koh
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

2.  New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites.

Authors:  J M Parker; D Guo; R S Hodges
Journal:  Biochemistry       Date:  1986-09-23       Impact factor: 3.162

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p.

Authors:  S J Bale; N C Dracopoli; M A Tucker; W H Clark; M C Fraser; B Z Stanger; P Green; H Donis-Keller; D E Housman; M H Greene
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

5.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

Authors:  S M Albelda; S A Mette; D E Elder; R Stewart; L Damjanovich; M Herlyn; C A Buck
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

6.  Expression of mutant p53 in melanoma.

Authors:  J R Stretch; K C Gatter; E Ralfkiaer; D P Lane; A L Harris
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma.

Authors:  J M Trent; F L Meyskens; S E Salmon; K Ryschon; S P Leong; J R Davis; D L McGee
Journal:  N Engl J Med       Date:  1990-05-24       Impact factor: 91.245

8.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.

Authors:  W H Clark; D E Elder; D Guerry; M N Epstein; M H Greene; M Van Horn
Journal:  Hum Pathol       Date:  1984-12       Impact factor: 3.466

Review 9.  Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma.

Authors:  J M Trent; F H Thompson; F L Meyskens
Journal:  Cancer Res       Date:  1989-01-15       Impact factor: 12.701

10.  Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus.

Authors:  J Wittbrodt; D Adam; B Malitschek; W Mäueler; F Raulf; A Telling; S M Robertson; M Schartl
Journal:  Nature       Date:  1989-10-05       Impact factor: 49.962

View more
  1 in total

1.  Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

Authors:  V A Tron; S Krajewski; H Klein-Parker; G Li; V C Ho; J C Reed
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.